Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ronopterin - vasopharm BIOTECH

Drug Profile

Ronopterin - vasopharm BIOTECH

Alternative Names: VAS-203

Latest Information Update: 03 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator vasopharm BIOTECH
  • Class Neuroprotectants; Pteridines; Small molecules
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Brain injuries

Most Recent Events

  • 01 Jul 2020 Vasopharm completes the phase III NOSTRA trial in Brain injuries in Germany, Spain, Austria, UK, France
  • 29 Jan 2020 vasopharm completes enrolment in the phase III NOSTRA III trial for Brain injuries in Austria, Spain, Germany, France and United Kingdom
  • 11 Jul 2019 vasopharm BIOTECH announces intention to submit MAA to EMA for Brain Injuries
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top